fda blenrep - Search News

Order byBest matchMost fresh

News

GSK, FDA and Blenrep

Zacks Investment Research on M… · 2h

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the proposed dosing regimen.

Continue reading

· 19h · on MSN

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

· 10h · on MSN

GSK Blood Cancer Drug Blenrep Fails to Win FDA Panel Support

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Fierce Pharma3d

As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results